Hester Biosciences has received reaffirmation in credit ratings for bank facilities at CARE BBB+; Stable / CARE A2 from CARE Ratings. Powered by Capital Market - Live News

Net profit of Hester Biosciences rose 100.49% to Rs 8.20 crore in the quarter ended September 2024 as against Rs 4.09 crore during the previous quarter ended September 2023. Sales rose 18.78% to Rs 83.69 crore in the quarter ended September 2024 as against Rs 70.46 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales83.6970.46 19 OPM %22.8918.75 - PBDT16.0711.05 45 PBT11.876.76 76 NP8.204.09 100 Powered by Capital Market - Live News

Hester Biosciences will hold a meeting of the Board of Directors of the Company on 28 October 2024.Powered by Capital Market - Live News

Net profit of Hester Biosciences rose 8.01% to Rs 6.34 crore in the quarter ended June 2024 as against Rs 5.87 crore during the previous quarter ended June 2023. Sales declined 6.35% to Rs 82.27 crore in the quarter ended June 2024 as against Rs 87.85 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales82.2787.85 -6 OPM %21.4516.35 - PBDT14.7314.31 3 PBT10.598.91 19 NP6.345.87 8 Powered by Capital Market - Live News

Hester Biosciences announced that the Annual General Meeting (AGM) of the company will be held on 29 August 2024.Powered by Capital Market - Live News